Use of SMSs to Improve Attendance to Cervical Cancer Follow-up Screening
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02509702 |
Recruitment Status :
Completed
First Posted : July 28, 2015
Last Update Posted : December 29, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cervical Cancer | Behavioral: Connected to Care | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 705 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Care Provider, Outcomes Assessor) |
Primary Purpose: | Screening |
Official Title: | Text Messages to Increase Attendance to Follow-up Cervical Cancer Screening Appointments Among HPV Positive Tanzanian Women (Connected2Care) |
Actual Study Start Date : | August 17, 2015 |
Actual Primary Completion Date : | October 6, 2019 |
Actual Study Completion Date : | October 6, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Connected to Care
The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months. There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
|
Behavioral: Connected to Care
10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment |
No Intervention: Control
The control group will receive standard care, which is a follow-up appointment at 14 months written on an appointment card.
|
- Effect of SMS intervention on attendance rate to follow-up screening appointment [ Time Frame: up to 14 months ]The effect measure of the intervention is the 14-month follow-up attendance rate for HPV positive women. The number of women in the intervention group that attend follow-up screening will be compared to the the number of women that attend follow-up screening in the control group.
- Acceptability of text message intervention [ Time Frame: Baseline + 2 years Follow-up (likert scale) ]6-point Likert scale (1: I do not like it at all - 6: I like it very much)
- Acceptability of text message intervention [ Time Frame: 2 years ]Qualitative interviews. Open-ended
- Cost-effectiveness of intervention [ Time Frame: Baseline + 14 months ]Incremental cost-effectiveness ratio
- Knowledge of cervical cancer and screening [ Time Frame: Baselie + 14 months ]16 item true-false questionaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years to 60 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Informed consent
- HPV positive
- Age 25 - 60 years
- Private mobile phone
Exclusion Criteria:
- Pregnant on day of enrolment
- Menstruating on day of enrolment
- Hysterectomy
- Diagnosed with cervical pre-cancer within past 12 months
- Diagnosed with cervical cancer
- Invalid mobile phone number
- Unreachable when trying to convey HPV positive result

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02509702
Tanzania | |
Mawenzi Regional Referral Hospital | |
Moshi, Kilimanjaro, Tanzania | |
Ocean Road Cancer Institute (ORCI) | |
Dar es Salaam, Tanzania, 3592 | |
Kilimanjaro Christian Medical Centre (KCMC) | |
Moshi, Tanzania, 3010 |
Study Chair: | Vibeke Rasch, MD | University of Southern Denmark | |
Study Chair: | Julius Mwaiselage, MD | Ocean Road Cancer Institute |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Marianne Andersen, Clinical professor, Odense University Hospital |
ClinicalTrials.gov Identifier: | NCT02509702 |
Other Study ID Numbers: |
Connected2Care |
First Posted: | July 28, 2015 Key Record Dates |
Last Update Posted: | December 29, 2021 |
Last Verified: | December 2021 |
Mobile health Screening Early detection of cancer HPV |
SMS intervention RCT Tanzania |
Uterine Cervical Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases |
Uterine Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Diseases |